Switch theme
Sign up to access all valuation multiples
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
2007
18
LTM Revenue $4.8M
Last FY EBITDA -$4.8M
$67.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Enzymatica has a last 12-month revenue (LTM) of $4.8M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Enzymatica achieved revenue of $4.8M and an EBITDA of -$4.8M.
Enzymatica expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Enzymatica valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.8M | XXX | $4.8M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $3.2M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 67% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$4.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -101% | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$5.4M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -114% | XXX | XXX | XXX |
| Net Profit | n/a | XXX | -$5.6M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | -117% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Enzymatica's stock price is SEK 3 (or $0).
Enzymatica has current market cap of SEK 709M (or $74.2M), and EV of SEK 643M (or $67.3M).
See Enzymatica trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $67.3M | $74.2M | XXX | XXX | XXX | XXX | $-0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Enzymatica has market cap of $74.2M and EV of $67.3M.
Enzymatica's trades at 14.1x EV/Revenue multiple, and -14.0x EV/EBITDA.
Equity research analysts estimate Enzymatica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Enzymatica's P/E ratio is not available.
See valuation multiples for Enzymatica and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $74.2M | XXX | $74.2M | XXX | XXX | XXX |
| EV (current) | $67.3M | XXX | $67.3M | XXX | XXX | XXX |
| EV/Revenue | 14.1x | XXX | 14.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -14.0x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -12.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -13.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -10.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEnzymatica's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.5M for the same period.
Enzymatica's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Enzymatica's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Enzymatica and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -101% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 182% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Enzymatica acquired XXX companies to date.
Last acquisition by Enzymatica was XXXXXXXX, XXXXX XXXXX XXXXXX . Enzymatica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Enzymatica founded? | Enzymatica was founded in 2007. |
| Where is Enzymatica headquartered? | Enzymatica is headquartered in Sweden. |
| How many employees does Enzymatica have? | As of today, Enzymatica has 18 employees. |
| Is Enzymatica publicy listed? | Yes, Enzymatica is a public company listed on STO. |
| What is the stock symbol of Enzymatica? | Enzymatica trades under ENZY ticker. |
| When did Enzymatica go public? | Enzymatica went public in 2015. |
| Who are competitors of Enzymatica? | Similar companies to Enzymatica include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Enzymatica? | Enzymatica's current market cap is $74.2M |
| What is the current revenue of Enzymatica? | Enzymatica's last 12 months revenue is $4.8M. |
| What is the current EV/Revenue multiple of Enzymatica? | Current revenue multiple of Enzymatica is 14.1x. |
| Is Enzymatica profitable? | Yes, Enzymatica is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
